Literature DB >> 19065349

Development of a vaccine against pandemic influenza viruses: current status and perspectives.

Petr O Ilyinskii1, Galini Thoidis, Alexander M Shneider.   

Abstract

The constant threat of a new influenza pandemic, which may be caused by a highly pathogenic avian influenza virus, necessitates the development of a vaccine capable of providing efficient, long-term, and cost-effective protection. Proven avenues for the development of vaccines against seasonal influenza as well as novel approaches have been explored over the past decade. Whereas significant insights are consistently being made, the generation of a highly efficient and cross-protective vaccine against the future pandemic influenza strain remains as the ultimate goal in the field. In this review, we re-examine these efforts and outline the scientific, political, and economic problems that befall this area of biotechnological research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19065349     DOI: 10.1080/08830180802295765

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  6 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

2.  Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection.

Authors:  Kevin B O'Brien; Stacey Schultz-Cherry; Laura J Knoll
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

Review 3.  Production of adenovirus vectors and their use as a delivery system for influenza vaccines.

Authors:  Sai V Vemula; Suresh K Mittal
Journal:  Expert Opin Biol Ther       Date:  2010-10       Impact factor: 4.388

4.  Specific temperature-induced perturbations of secondary mRNA structures are associated with the cold-adapted temperature-sensitive phenotype of influenza A virus.

Authors:  Andrey Chursov; Sebastian J Kopetzky; Ignaty Leshchiner; Ivan Kondofersky; Fabian J Theis; Dmitrij Frishman; Alexander Shneider
Journal:  RNA Biol       Date:  2012-09-20       Impact factor: 4.652

Review 5.  Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.

Authors:  Vladimir L Gabai; Victor I Shifrin
Journal:  Int Rev Immunol       Date:  2014-10       Impact factor: 5.311

6.  Findings from a household randomized controlled trial of hand washing and face masks to reduce influenza transmission in Bangkok, Thailand.

Authors:  James M Simmerman; Piyarat Suntarattiwong; Jens Levy; Richard G Jarman; Suchada Kaewchana; Robert V Gibbons; Ben J Cowling; Wiwan Sanasuttipun; Susan A Maloney; Timothy M Uyeki; Laurie Kamimoto; Tawee Chotipitayasunondh
Journal:  Influenza Other Respir Viruses       Date:  2011-02-17       Impact factor: 4.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.